{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:54:03Z","timestamp":1788501243843,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>In the OPTIMISMM trial, pomalidomide\/bortezomib\/dexamethasone (PVd) significantly prolonged median progression\u2010free survival (PFS) versus bortezomib\/dexamethasone (Vd) in lenalidomide\u2010exposed relapsed and refractory multiple myeloma (RRMM). We report final overall survival (OS) and updated efficacy analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with RRMM who had 1\u20133 prior regimens, including lenalidomide (\u2265\u20092\u2009cycles), were assigned (1:1) to PVd or Vd. Primary endpoint: PFS. Prespecified secondary endpoint: OS. Prespecified exploratory endpoints: PFS2 and subgroup efficacy analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>With an overall event rate of 70.0%, OS data were mature in the intent\u2010to\u2010treat population (<jats:italic>N<\/jats:italic>\u2009=\u2009559). After median follow\u2010up of 64.5\u2009months (data cutoff: May 13, 2022), median OS was 35.6\u2009months with PVd versus 31.6\u2009months with Vd (HR 0.94, 95% CI 0.77\u20131.15, <jats:italic>p<\/jats:italic>\u2009=\u20090.571); adjusting for subsequent therapies, OS improved with PVd versus Vd (HR 0.76, 95% CI 0.619\u20130.931, <jats:italic>p<\/jats:italic>\u2009=\u20090.008). Median PFS2 was 22.1 versus 16.9\u2009months, respectively (HR 0.77, 95% CI 0.64\u20130.94, nominal <jats:italic>p<\/jats:italic>\u2009=\u20090.008). Treatment\u2010emergent adverse events led to study drug discontinuation in 92 (33.1%) and 53 (19.6%) patients in PVd and Vd arm, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Findings showed a nonsignificant trend towards improved OS with PVd versus Vd. PFS2 favored PVd, supporting its use in RRMM.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14365","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:00:30Z","timestamp":1736316030000},"page":"822-831","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the <scp>OPTIMISMM<\/scp> Trial"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul","family":"Richardson","sequence":"first","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology Dana\u2013Farber Cancer Institute, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksa\u00e7","sequence":"additional","affiliation":[{"name":"Istinye University Ankara Liv Hospital  Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d'Oncologia and Institut Josep Carreras Hospital Germans Trias i Pujol  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindriska","family":"Lindsay","sequence":"additional","affiliation":[{"name":"East Kent Hospitals University NHS Foundation Trust Kent and Canterbury Hospital  Canterbury UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[{"name":"Oslo Myeloma Center, Department of Hematology Oslo University Hospital  Oslo Norway"},{"name":"KG Jebsen Center for B Cell Malignancies University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Galli","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit ASST Papa Giovanni XXIII  Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcnci","family":"Ya\u011fc\u0131","sequence":"additional","affiliation":[{"name":"Gazi University Medical Facility  Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Larocca","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Torino  Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology University Medical Center Hamburg\u2013Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[{"name":"Celgene, a Bristol\u2010Myers Squibb Company  Summit New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Donahue","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Acosta","sequence":"additional","affiliation":[{"name":"Celgene International S\u00e0rl, a Bristol\u2010Myers Squibb Company  Boudry Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Peluso","sequence":"additional","affiliation":[{"name":"Celgene International S\u00e0rl, a Bristol\u2010Myers Squibb Company  Boudry Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine National and Kapodistrian University of Athens  Athens Greece"},{"name":"Department of Medicine Korea University  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096"},{"key":"e_1_2_8_3_1","unstructured":"National Comprehensive Cancer Network. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma V.3.2023. \u00a9 National Comprehensive Cancer Network Inc. 2022. All rights reserved. Accessed June 14 2023. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way https:\/\/www.nccn.org\/."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01021-3"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.66"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.119"},{"key":"e_1_2_8_9_1","unstructured":"European Medicines Agency Sarclisa (isatuximab) Summary of Product Characteristics 2023 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/sarclisa\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_8_10_1","unstructured":"European Medicines Agency Empliciti (elotuzumab) Summary of Product Characteristics London United Kingdom European Medicines Agency 2022 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/empliciti\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_8_11_1","unstructured":"Janssen Darzalex (daratumumab) Prescribing Information 2023 https:\/\/www.janssenlabels.com\/package\u2010insert\/product\u2010monograph\/prescribing\u2010information\/DARZALEX\u2010pi.pdf."},{"key":"e_1_2_8_12_1","unstructured":"Bristol Myers Squibb Empliciti (elotuzumab) Prescribing Information 2022 https:\/\/packageinserts.bms.com\/pi\/pi_empliciti.pdf."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782961"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30756-7"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.03.018"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1666381"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.10.006"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00757-8"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163483"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8007"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139785"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02734"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.356"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.01.011"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.173"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T12:08:37Z","timestamp":1754914117000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/ejh.14365"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14365","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"2024-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}